Gsk (GSK) Receivables - Other (2012 - 2025)

Gsk (GSK) has 14 years of Receivables - Other data on file, last reported at $1.5 billion in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Other rose 38.7% year-over-year to $1.5 billion; the trailing twelve-month figure through Dec 2025 stood at $1.5 billion (up 38.7% YoY), and the FY2025 full-year result was $1.5 billion, up 39.27% from the prior year.
• Receivables - Other was $1.5 billion for Q4 2025 at Gsk, up from $1.1 billion in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $15.2 billion in Q1 2022 to a low of $1.1 billion in Q4 2024.
• A 5-year average of $3.7 billion and a median of $1.5 billion in 2022 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other retreated 15.74% in 2022 and jumped 38.7% in 2025, its largest moves.
• Gsk's Receivables - Other stood at $1.7 billion in 2021, then slipped by 15.74% to $1.4 billion in 2022, then declined by 9.81% to $1.3 billion in 2023, then fell by 15.19% to $1.1 billion in 2024, then surged by 38.7% to $1.5 billion in 2025.
• Per Business Quant data, the three most recent Receivables - Other figures were $1.5 billion in Q4 2025, $1.1 billion in Q4 2024, and $1.3 billion in Q4 2023.